Cargando…

Clinical picture and outcome of Serious Adverse Events in the treatment of Onchocerciasis

Ivermectin (Mectizan(®)) is the only drug currently recommended for the treatment and control of onchocerciasis. Serious adverse events rarely occur during treatment, except in subjects heavily infected with Loa Loa. This review of drug-related serious adverse events in the treatment of onchocercias...

Descripción completa

Detalles Bibliográficos
Autor principal: Awadzi, Kwablah
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2003
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2147654/
https://www.ncbi.nlm.nih.gov/pubmed/14975063
http://dx.doi.org/10.1186/1475-2883-2-S1-S6
_version_ 1782144490224484352
author Awadzi, Kwablah
author_facet Awadzi, Kwablah
author_sort Awadzi, Kwablah
collection PubMed
description Ivermectin (Mectizan(®)) is the only drug currently recommended for the treatment and control of onchocerciasis. Serious adverse events rarely occur during treatment, except in subjects heavily infected with Loa Loa. This review of drug-related serious adverse events in the treatment of onchocerciasis therefore revisited the pre-Mectizan(® )reference drugs, DEC and suramin, and other candidate drugs studied extensively for the treatment of human onchocerciasis. The benzimidazole carbamate derivatives and the antibiotic doxycycline were excluded, since no serious adverse events have been reported regarding their use. Using recommended definitions, serious adverse events reported or observed after the use of each drug were summarised, the level of attribution determined, and the results tabulated. Prominence was given to treatment-related deaths. The clinical picture of severe symptomatic postural hypotension is described and used to illustrate the difference between the severity and the seriousness of an adverse event. The epidemiology, management and outcome of serious adverse events are presented. The role of future research is discussed.
format Text
id pubmed-2147654
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-21476542007-12-20 Clinical picture and outcome of Serious Adverse Events in the treatment of Onchocerciasis Awadzi, Kwablah Filaria J Review Ivermectin (Mectizan(®)) is the only drug currently recommended for the treatment and control of onchocerciasis. Serious adverse events rarely occur during treatment, except in subjects heavily infected with Loa Loa. This review of drug-related serious adverse events in the treatment of onchocerciasis therefore revisited the pre-Mectizan(® )reference drugs, DEC and suramin, and other candidate drugs studied extensively for the treatment of human onchocerciasis. The benzimidazole carbamate derivatives and the antibiotic doxycycline were excluded, since no serious adverse events have been reported regarding their use. Using recommended definitions, serious adverse events reported or observed after the use of each drug were summarised, the level of attribution determined, and the results tabulated. Prominence was given to treatment-related deaths. The clinical picture of severe symptomatic postural hypotension is described and used to illustrate the difference between the severity and the seriousness of an adverse event. The epidemiology, management and outcome of serious adverse events are presented. The role of future research is discussed. BioMed Central 2003-10-24 /pmc/articles/PMC2147654/ /pubmed/14975063 http://dx.doi.org/10.1186/1475-2883-2-S1-S6 Text en
spellingShingle Review
Awadzi, Kwablah
Clinical picture and outcome of Serious Adverse Events in the treatment of Onchocerciasis
title Clinical picture and outcome of Serious Adverse Events in the treatment of Onchocerciasis
title_full Clinical picture and outcome of Serious Adverse Events in the treatment of Onchocerciasis
title_fullStr Clinical picture and outcome of Serious Adverse Events in the treatment of Onchocerciasis
title_full_unstemmed Clinical picture and outcome of Serious Adverse Events in the treatment of Onchocerciasis
title_short Clinical picture and outcome of Serious Adverse Events in the treatment of Onchocerciasis
title_sort clinical picture and outcome of serious adverse events in the treatment of onchocerciasis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2147654/
https://www.ncbi.nlm.nih.gov/pubmed/14975063
http://dx.doi.org/10.1186/1475-2883-2-S1-S6
work_keys_str_mv AT awadzikwablah clinicalpictureandoutcomeofseriousadverseeventsinthetreatmentofonchocerciasis